IMMY Imprimis Pharmaceuticals, Inc. (delisted)

EDISON EQUITY RESEARCH: IMPRIMIS PHARMACEUTICALS - BUILDING REVENUE STREAMS

Imprimis is poised to achieve meaningful revenue in 2015. In 2014 it increased capacity by acquiring two compounding pharmacies and thus increased sales of its ophthalmic products. 2015 has seen continued adoption of the Dropless Therapy cataract surgery injection and the acquisition of the exclusive licence to Hep-Lido-A (HLA), which sold 80k units last year. Revenue is likely to rise in 2015, with strong upside potential if targeted increases in market share are achieved.

Imprimis is a pharmaceutical company focused on compounding specialty products for physicians. Products include an intraocular injectable steroid and antibiotic combination used at the conclusion of cataract surgery and an intravesical instillation product for the treatment of interstitial cystitis.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports